The present invention provides methods of treating a disease or disorder in a subject comprising administering to the subject a therapeutically effective amount of an agent that modulates RIOK2.

It pertains to a novel platform for the sustained release of Type-1 diabetes antigens. More specifically. it provides a combination of dual sized hydrogel particles for the delivery of Type-1 diabetes antigens and multi-component adjuvants to confer immune tolerance.